p27/CDKN1B Cancer Research Results

p27/CDKN1B, p27kip1: Click to Expand ⟱
Source:
Type:
The cyclin-dependent kinase (Cdk) inhibitor p27 regulates cell proliferation, cell motility and apoptosis, and is inactivated through various means in many types of human cancer.

CDKN1B - Cyclin-Dependent Kinase Inhibitor 1B / p27

Abbreviation: CDKN1B, p27, p27Kip1

Type: Cyclin-dependent kinase inhibitor / cell-cycle regulator

Function: CDKN1B/p27 inhibits cyclin-CDK complexes, particularly cyclin E-CDK2 and cyclin A-CDK2, thereby restricting G1/S cell-cycle progression. It also regulates differentiation, transcription, cytoskeletal organization, cell migration, and cellular responses to growth-factor signaling.

Cancer: ↕ Context-dependent, but predominantly tumor-suppressive. Reduced nuclear p27 expression or functional loss can promote uncontrolled proliferation, tumor progression, and treatment resistance. However, cytoplasmic p27 can acquire CDK-independent pro-oncogenic functions that promote cell motility, invasion, and aggressive tumor behavior.
Scientific Papers found: Click to Expand⟱
6901- FIS,    Fisetin induces G2/M phase arrest and caspase-mediated cleavage of p21Cip1 and p27Kip1 leading to apoptosis and tumor growth inhibition in HNSCC
- in-vivo, HNSCC, CAL33
TumCG↓, TumCD↑, selectivity↑, TumCCA↑, CDC25↓, CDK1↓, CycB/CCNB1↓, P53↑, DNAdam↑, Apoptosis↑, γH2AX↑, cl‑PARP↑, other↝, JNK↑, PI3K↓, Akt↓, ERK↓, EGFR↓, STAT3↓, TumAuto↑, Dose↝, TumVol↓, Ki-67↓, cl‑Casp3↑, P21↓, p27/CDKN1B↓,
7645- IP6,  Ins,    Anticancer Properties of Inositol Hexaphosphate and Inositol: An Overview
AntiCan↑, TumCP↓, Apoptosis↑, Diff↑, p27/CDKN1B↓, pRB↓, PI3K↓, RAS↓, ERK↓, Akt↓, NF-kB↓, Inflam↓, AntiTum↓,
7690- IP6,  Ins,    Inositol Hexaphosphate (IP6) and Colon Cancer: From Concepts and First Experiments to Clinical Application
- Review, Colon, NA
AntiCan↑, Imm↑, antiOx↑, TumCP↓, Diff↑, TumCG↓, eff↑, P21↓, p27/CDKN1B↓, pRB↓, TumCCA↑, PI3K↓, Akt↓, PKCδ↓, RAS↓, ERK↓, NF-kB↓, Inflam↓, MMP9↓, IronCh↑, NK cell↑, selectivity↑, ChemoSen↑, chemoP↑, toxicity↓, Remission↑,
7699- IP6,    IP6: From Seeds to Science—A Natural Compound’s Path to Clinical Promise
- Review, Var, NA
*Iron∅, ChemoSen↑, *cardioP↑, neuroP↑, IronCh∅, P21↓, p27/CDKN1B↓, p‑pRB↓, PI3K↓, Akt↓, NF-kB↓, Inflam↓, TumW↓, TumCI↓, TumMeta↓, Imm↑, Diff↑, selectivity↑, toxicity↓, RenoP↑, QoL↑,
8148- lamb,    Anti-Cancer Effect of Lambertianic Acid by Inhibiting the AR in LNCaP Cells
- in-vitro, Pca, LNCaP
*antiAll↑, *Bacteria↓, AR↓, PSA↓, TumCCA↑, CDK4↓, CDK6↓, cycD1/CCND1↓, P53↑, P21↑, p27/CDKN1B↓, Apoptosis↑, cl‑Casp9↑, cl‑Casp3↑, cl‑PARP↑, BAX↑, Bcl-2↓, Dose↝,
8156- lamb,    A review on chemistry, source and therapeutic potential of lambertianic acid
- Review, Var, NA
*Obesity↓, *AntiCan↑, *AMPK↑, *β-HEX↓, NA↑, TumCCA↑, AMPK↑, ACC↑, p‑Akt↓, FOXM1↓, CycB/CCNB1↓, XIAP↓, Bcl-2↓, p‑STAT3↓, p‑NF-kB↓, Bcl-xL↓, survivin↓, VEGF↓, COX2/PTGS2↓, cMyc↓, IL6↓, TNF-α↓, ROS↑, STK11/LKB1↑, cl‑Casp3↑, cl‑PARP↑, eff↑, AR↓, TumCP↓, p‑P53↓, P21↓, p27/CDKN1B↓, cycD1/CCND1↓, CDK4↓, PSA↓, STAT3↓, ac‑p65↓, *antiAll↑,
3275- Lyco,    Multifaceted Effects of Lycopene: A Boulevard to the Multitarget-Based Treatment for Cancer
- Review, Var, NA
TumCCA↑, cycD1/CCND1↓, cycE/CCNE↓, CDK2↓, CDK4↓, P21↑, P53↑, GSK‐3β↓, p27/CDKN1B↓, Akt↓, mTOR↓, ROS↓, MMPs↓, TumCI↓, TumCMig↓, NF-kB↓, *iNOS↓, *COX2/PTGS2↓, lipid-P↓, GSH↑, NRF2↑,
5795- MET,    Metformin: A Review of Potential Mechanism and Therapeutic Utility Beyond Diabetes
- Review, AD, NA - Review, Park, NA - Review, Diabetic, NA
*AntiDiabetic↑, *AMPK↑, *glyC↓, *ROS↓, *cardioP↑, *neuroP↑, *Half-Life↝, *toxicity↝, *BioAv↑, *glucose↓, *AGEs↓, AntiCan↑, Risk↓, TumCP↓, Apoptosis↑, TumCCA↑, cycD1/CCND1↓, pRB↓, p27/CDKN1B↓, mTOR↓, Casp↑, ROS↑, MMP↓, ChemoSen↑, *hepatoP↑, *CRM↑, *Insulin↓,
2982- RES,    The flavonoid resveratrol suppresses growth of human malignant pleural mesothelioma cells through direct inhibition of specificity protein 1
- in-vitro, Melanoma, MSTO-211H
tumCV↓, Apoptosis↑, Sp1/3/4↓, p27/CDKN1B↓, P21↓, cycD1/CCND1↓, Mcl-1↓, survivin↓,
6456- TUR,    Ar-turmerone inhibits the proliferation and mobility of glioma by downregulating cathepsin B
- in-vitro, GBM, U251 - in-vitro, GBM, U87MG - in-vitro, GBM, LN229
TumCP↓, TumCCA↑, CTSB↓, cl‑p27/CDKN1B↓,

Showing Research Papers: 1 to 10 of 10

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 10

Pathway results for Effect on Cancer / Diseased Cells:


NA, unassigned(tgid=0) ⓘ

NA↑, 1,  

Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 1,   GSH↑, 1,   lipid-P↓, 1,   NRF2↑, 1,   ROS↓, 1,   ROS↑, 2,  

Metal & Cofactor Biology(tgid=2) ⓘ

IronCh↑, 1,   IronCh∅, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

CDC25↓, 1,   MMP↓, 1,   XIAP↓, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

ACC↑, 1,   AMPK↑, 1,   cMyc↓, 1,   STK11/LKB1↑, 1,  

Cell Death(tgid=5) ⓘ

Akt↓, 5,   p‑Akt↓, 1,   Apoptosis↑, 5,   BAX↑, 1,   Bcl-2↓, 2,   Bcl-xL↓, 1,   Casp↑, 1,   cl‑Casp3↑, 3,   cl‑Casp9↑, 1,   JNK↑, 1,   Mcl-1↓, 1,   p27/CDKN1B↓, 9,   cl‑p27/CDKN1B↓, 1,   survivin↓, 2,   TumCD↑, 1,  

Kinase & Signal Transduction(tgid=6) ⓘ

Sp1/3/4↓, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

other↝, 1,   pRB↓, 3,   p‑pRB↓, 1,   tumCV↓, 1,  

Autophagy & Lysosomes(tgid=9) ⓘ

TumAuto↑, 1,  

DNA Damage & Repair(tgid=10) ⓘ

DNAdam↑, 1,   P53↑, 3,   p‑P53↓, 1,   cl‑PARP↑, 3,   γH2AX↑, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

CDK1↓, 1,   CDK2↓, 1,   CDK4↓, 3,   CycB/CCNB1↓, 2,   cycD1/CCND1↓, 5,   cycE/CCNE↓, 1,   P21↓, 5,   P21↑, 2,   TumCCA↑, 7,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

CTSB↓, 1,   Diff↑, 3,   ERK↓, 3,   FOXM1↓, 1,   GSK‐3β↓, 1,   mTOR↓, 2,   PI3K↓, 4,   RAS↓, 2,   STAT3↓, 2,   p‑STAT3↓, 1,   TumCG↓, 2,  

Migration(tgid=13) ⓘ

Ki-67↓, 1,   MMP9↓, 1,   MMPs↓, 1,   PKCδ↓, 1,   TumCI↓, 2,   TumCMig↓, 1,   TumCP↓, 5,   TumMeta↓, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

EGFR↓, 1,   VEGF↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

COX2/PTGS2↓, 1,   IL6↓, 1,   Imm↑, 2,   Inflam↓, 3,   NF-kB↓, 4,   p‑NF-kB↓, 1,   NK cell↑, 1,   ac‑p65↓, 1,   PSA↓, 2,   TNF-α↓, 1,  

Hormonal & Nuclear Receptors(tgid=20) ⓘ

AR↓, 2,   CDK6↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

ChemoSen↑, 3,   Dose↝, 2,   eff↑, 2,   selectivity↑, 3,  

Clinical Biomarkers(tgid=22) ⓘ

AR↓, 2,   EGFR↓, 1,   FOXM1↓, 1,   IL6↓, 1,   Ki-67↓, 1,   PSA↓, 2,  

Functional Outcomes(tgid=23) ⓘ

AntiCan↑, 3,   AntiTum↓, 1,   chemoP↑, 1,   neuroP↑, 1,   QoL↑, 1,   Remission↑, 1,   RenoP↑, 1,   Risk↓, 1,   toxicity↓, 2,   TumVol↓, 1,   TumW↓, 1,  
Total Targets: 105

Pathway results for Effect on Normal Cells:


NA, unassigned(tgid=0) ⓘ

antiAll↑, 2,   β-HEX↓, 1,  

Redox & Oxidative Stress(tgid=1) ⓘ

Iron∅, 1,   ROS↓, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

Insulin↓, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

AMPK↑, 2,   CRM↑, 1,   glucose↓, 1,   glyC↓, 1,  

Cell Death(tgid=5) ⓘ

iNOS↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

COX2/PTGS2↓, 1,  

Protein Aggregation(tgid=19) ⓘ

AGEs↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↑, 1,   Half-Life↝, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiCan↑, 1,   AntiDiabetic↑, 1,   cardioP↑, 2,   hepatoP↑, 1,   neuroP↑, 1,   Obesity↓, 1,   toxicity↝, 1,  

Infection & Microbiome(tgid=24) ⓘ

Bacteria↓, 1,  
Total Targets: 22

Scientific Paper Hit Count for: p27/CDKN1B, p27kip1
3 IP6 (Inositol 1,2,3,4,5,6-hexakisphosphate)
2 Inositol
2 lambertianic acid
1 Fisetin
1 Lycopene
1 Metformin
1 Resveratrol
1 Turmerones
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:1  prod#:%  Target#:468  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page